Shares of GlaxoSmithKline plc (LON:GSK) have received a consensus rating of “Hold” from the twenty-two research firms that are presently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is GBX 1,703.70 ($22.00).

Several brokerages have weighed in on GSK. UBS AG set a GBX 1,600 ($20.66) price target on GlaxoSmithKline plc and gave the stock a “neutral” rating in a report on Monday, May 29th. Bryan, Garnier & Co reissued a “buy” rating and issued a GBX 1,750 ($22.60) price target on shares of GlaxoSmithKline plc in a report on Wednesday, May 31st. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a GBX 1,900 ($24.54) price target on shares of GlaxoSmithKline plc in a report on Wednesday, May 31st. Liberum Capital reissued a “buy” rating and issued a GBX 1,900 ($24.54) price target on shares of GlaxoSmithKline plc in a report on Wednesday, June 14th. Finally, Deutsche Bank AG reissued a “hold” rating and issued a GBX 1,720 ($22.21) price target on shares of GlaxoSmithKline plc in a report on Friday, June 30th.

In other news, insider Manvinder Singh Banga purchased 2,267 shares of the stock in a transaction dated Wednesday, July 26th. The shares were purchased at an average cost of GBX 1,599 ($20.65) per share, with a total value of £36,249.33 ($46,815.61). Also, insider Victoria Whyte sold 4,820 shares of GlaxoSmithKline plc stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of GBX 1,693 ($21.86), for a total value of £81,602.60 ($105,388.87). Insiders bought 3,152 shares of company stock worth $5,055,023 over the last ninety days.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/17/glaxosmithkline-plc-gsk-receives-average-rating-of-hold-from-analysts.html.

GlaxoSmithKline plc (GSK) opened at 1454.00 on Friday. GlaxoSmithKline plc has a 12 month low of GBX 1,446.50 and a 12 month high of GBX 1,745.56. The stock’s market cap is GBX 71.07 billion. The firm has a 50-day moving average price of GBX 1,507.18 and a 200-day moving average price of GBX 1,610.52.

The firm also recently disclosed a dividend, which will be paid on Thursday, October 12th. Stockholders of record on Thursday, August 10th will be given a GBX 19 ($0.25) dividend. This represents a dividend yield of 1.23%. The ex-dividend date of this dividend is Thursday, August 10th.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.